

## Definitions

*TB exposure:* 5% → infection. Incubation. 2-3wk. Mantoux +ve after 2-3mo.

*Latent TB infection (LTBI):* Positive Mantoux but asymptomatic, normal CXR

*TB Disease/Active TB:* Symptomatic or positive CXR. It may be: Primary or Secondary.

*Primary infection:* First infection - usually lung. *Miliary TB:* multiorgan dissemination.

*Secondary (reactivation) infection:* ↓ immune fn e.g. malnutrition, AIDS, immunosuppressants

## Pathophysiology

- Chronic granulomatous disease caused mostly by *Mycobacterium tuberculosis* (MTB). Occ. *M. bovis* or *M. africanum*. Aerobic, non-sporing, bacilli. Slow-growing & hardy.
- Humans only known reservoirs of *M. tuberculosis* infection.
- Primary infection results from aerosol distribution from infected individuals.
- Alveolar macrophages unable to destroy MTB but infected macrophages reach regional LN and beyond (kidney, bones, meninges, apical posterior areas of the lung) where cell-mediated immune response initiated & terminates growth of MTB in ~2-3 weeks by CD8 suppressor T cells in lung → caseating granulomas (tubercles). Hence site of 1<sup>st</sup> infection usually heals with caseation & encapsulation but can grow & cause symptoms.
- Initial infection site+adjacent LN = primary complex (or Ghon focus). May be calcified.
- Most people infected with *M. tuberculosis* do not go on to have active disease.
- Disease may result from:
  - Progression of 1<sup>o</sup> complex → hilar & mediastinal ↑LN & bronchial collapse.
  - Spread by progressive caseation and cavitation through the adjacent bronchi.
  - Spread through the bloodstream and lymphatics occurs more often in children and can progress to miliary TB (when several organs or tissues are infected).
  - Bacteria released into the bloodstream can produce disseminated disease meningeal, skeletal, pleural, cutaneous, genitourinary, gastrointestinal TB.
  - Reactivation of TB that has remained dormant (usually in post. apical lung).
- Time-line - greatest risk of progressive disease is <1yr from infection.
  - 1-3m: Cell-mediated response (necessary for pos Mantoux), 2-6m: Miliary TB or TB meningitis, 4-10m: LN disease/pleural effusion, 10m-years: Adult-like disease.

## Epidemiology


Prevalence: ~1/3 world population infected.

↑ Incidence. Active TB incidence:  $9 \times 10^6$  cases/yr.

2<sup>nd</sup> commonest cause of infectious death.

## Risk Factors

- Close contact with TB-infected adult: especially household & ED healthcare workers.
- Ethnic minority groups
- Poverty, malnutrition, homeless, alcoholics and IVDU
- HIV Positive and other immunocompromised patients
- Elderly patients - latent TB may reactivate in elderly patients.
- Other conditions: Smoking, debilitating disease, DMs, ESRF, silicosis, and gastrectomy
- Children <5y: particularly susceptible to mycobacterial infection as immuno-immature
- Vertical transmission to babies of infected mothers.



## Presentation

- Insidious onset.
- Primary infection usually asymptomatic.
- Secondary infection may be non-specific, need high index of suspicion
- TB can affect all organs and body systems.
- Extra-pulmonary TB more common in children/immunosuppressed

*General symptoms:* fatigue, malaise, fever, weight loss, anorexia, failure to thrive, PUO.

*Pulmonary:* Chronic cough with purulent±bloodstained sputum. May → lobar collapse, bronchiectasis, pleural effusion, pneumonia.

*GUS:* "sterile" pyuria. There may be kidney lesions, salpingitis, abscesses and infertility in females and swelling of the epididymis in males.

*MSK:* arthritis, osteomyelitis and abscess formation (e.g. vertebral - Pott's disease).

*CNS:* tuberculous meningitis and tuberculomas.

*GIT:* mainly ileocaecal lesions but occasional peritoneal spread causes ascites

*LN:* hilar, paratracheal, cervical, or superficial node involvement. Scrofula.

*Skin:* Erythema nodosum, erythema induratum.

## Investigations

*Intradermal Tuberculin skin test (Mantoux):* Purified protein derivative (PPD) reaction read at 48-72hr & indicates exposure (latent or present infection) if induration >5, 10 or 15mm depending on pre-test risk. False +ve if recent BCG or non-TB mycobacterial infection. False -ve if young child, immunosuppressed, infection<3mo, recent chickenpox/rubella, adult anergy.

### *Cultures*

- Samples: 3+ spontaneous sputum samples for MC&S (incl an early morning sample) or, esp in children, induced sputum, gastric aspirate, NPA, BAL, or string test.
- Can do FNA or excision (not incision) biopsy
- Ziehl-Nielson stain and rapid direct microscopy for acid/alcohol fast bacilli
- Culture on a Lowenstein-Jensen slope (4-8wks)
- Antibiotic sensitivity cultures take a further 3-4 weeks.

*CXR:* Pulmonary TB is unlikely with a normal CXR.

- Primary TB - Normally base of upper lobe or top of lower lobe ± pleural effusion. Hilar LNs - Lateral XR may show nodes post & lat to trachea. (1° or Ghon Complex = calcified hilar LN+peripheral nodule).
- Reactivated TB - no pleural effusion and lesions in posterior apex. Patchy or nodular shadows, loss of volume, fibrosis ± cavitation, calcification.
- Miliary TB - uniform 1-2mm shadows throughout lung.

### *Non-respiratory TB:*

- Consider biopsy and needle aspiration for MC&S
- Early morning urine for GUS disease.
- LP for meningitis
- CXR should be done for co-existing respiratory TB

### *Other tests:*

- Serological tests have good negative predictive value except in HIV.
- Interferon-gamma release assays e.g. Quantiferon are similarly sens but more specific than Mantoux. Unaffected by BCG but still don't separate latent & active infection.
- PCR is possible (e.g. GeneXpert - 70% sens) but not widely available.

## Management

*Antituberculous drugs* - Combination therapy to reduce resistance.

- All sites except CNS: quadruple Rx (isoniazid, rifampicin, pyrazinamide & ethambutol) x 2mo then (isoniazid and rifampicin) x 4mo.
- Meningitis: quadruple Rx x 2mo then (isoniazid and rifampicin) x 10mo. No evidence of need for intrathecal streptomycin.

### *First line drugs*

- **Isoniazid**: Bactericidal. Renal excretion. **SE**: peripheral neuropathy (prophylactic pyridoxine if DM, alcoholics, malnourished, CRF or HIV), hepatitis
- **Rifampicin**: mycobacterial RNA polymerase inhibitor. Hepatic CP450 met & induction. **SE**: orange body fluids, ARF, thrombocytopenic purpura, ↑metabolism of OCP, warfarin, sulphonylureas & steroids, hepatitis
- **Pyrazinamide**: Bacteriostatic. Renal excretion. **SE**: arthralgia, hepatitis, rash
- **Ethambutol**: Bacteriostatic. Excreted in urine and faeces. **SE**: ↓Visual acuity/fields, optic neuritis, colour blindness.

### *Second line drugs*

- E.g. amikacin, capreomycin, cycloserine, macrolides (azithromycin, clarithromycin) and quinolones (moxifloxacin, levofloxacin). Streptomycin rarely used.

### *Steroids*

- Give **prednisolone** 20-40mg [child 1-2mg/kg] PO OD x 2-3wk then taper if:
  - Meningitis, lobar collapse 2<sup>o</sup> to lymphadenopathy, renal or adrenal TB, moribund

### *Chemoprophylaxis for latent TB infection:*

- **Isoniazid** x 6mo OR **isoniazid+rifampicin** x 3mo.

### *Multidrug resistant TB (MDR-TB)*

- Long courses of triple therapy ± 2<sup>nd</sup> line drugs
- Consider surgical excision of lesions

### *Risk factors for drug resistance include:*

- Previous treatment for TB
- Prior failure of TB treatment
- Contact with a known case of drug resistant TB
- Immigration from areas of high resistance
- HIV-positive status
- Age profile (highest rates are between ages 25 and 44)
- Male gender

## Prognosis

- Prognosis very much depends on the extent and type of infection.
- Miliary TB, disseminated TB and tubercular meningitis are associated a poor prognosis.

## Prevention

- Isolation, face mask use.
- Compliance & supervised treatment.
- Isoniazid preventative therapy (6mo) for children (close contact, asymptomatic AND <5y or immunocompromised)
- Public Health: Notification, contact tracing & Immigration screening.
- BCG vaccination. In high incidence areas BCG programme can be useful.
- Prevent/treat HIV early
- Post-exposure prophylaxis